UPDATE : Monday, September 7, 2020
상단여백
HOME Pharma
Leo Pharma Korea launches Enstilum foam for psoriasis
  • By Marian Chu
  • Published 2018.05.31 17:47
  • Updated 2018.05.31 17:47
  • comments 0
Enstilum foam

Leo Pharma Korea has launched a spray-on, topical treatment for psoriasis called Enstilum foam (calcipotriol/betamethasone dipropionate), on the domestic market.

“We at Leo pharma are proud and extremely excited to help more Korean patients with our product Enstilum,” said Kelly Lauson, general manager of Leo Pharma Korea.

Psoriasis is a long-term (chronic) inflammatory skin condition characterized by skin cells multiplying rapidly, leading to red plaques covered with white scales. It is also associated with psoriatic arthritis.

In Korea, the condition affects about 0.5 percent of the entire population with around 80 percent of patients using topical treatments, said Professor Kim Dong-hyun from Budang Cha Hospital, Department of Dermatology.

The U.S. Food and Drug Administration approved Enstilum foam in 2015 and the Ministry of Food and Drug Safety in December 2016, to treat psoriasis patients of 18 or older.

The foam formulation is a combination of calcipotriol - a vitamin-D derivative - and betamethasone dipropionate, which has proven to be more effective in normalizing psoriasis skin cells than a single ingredient therapy, according to Leo Pharma. The foam also acts more readily to promote anti-inflammatory responses, it added.

Dr. Linda F. Steingold from Henry Ford Medical Center pointed out that the foam, which can be used to spray on hard-to-reach body parts, would be an essential therapy for patients who have mild to moderate psoriasis.

“Why are we interested in a new topical agent? When we look at psoriasis patients, the majority have mild to moderate disease, and around 80 percent use topical therapy alone,” Steingold said.

The phase 3 PSO-FAST trial on 426 psoriasis patients that divided patients into an Enstilum and placebo group showed that 72 percent in the Enstilum arm saw a reduction in the mPASI score by four weeks compared to the baseline. Results also showed a clinically significant effect on quality of life when applying the Dermatology Quality of Life Index.

The phase 3 PSO-ABLE study also indicated 52.1 percent of patients who used the foam reached a Mpasi75 score for four weeks, which was higher than the 34.6 percent of patients who used standard gel-type combination therapy for eight weeks.

yjc@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>

Other articles by Marian Chu
iconMost viewed
Comments 0
More
Please leave the first comment.
여백
여백
여백
Back to Top